* Genzyme Corp., of Cambridge, Mass., has entered its secondresearch collaboration in a month to develop a gene therapy fortreatment of Gaucher's disease. The most recent is with University ofPittsburgh Professor John Barranger. In early October, the companysigned an agreement with Netherlands-based IntroGene B.V.Genzyme already markets two drugs, Ceredase and Cerezyme, fortreatment of Gaucher's disease.* InSite Vision Inc., of Alameda, Calif., has completed enrollment ofmore than 645 patients with ocular hypertension or open-angleglaucoma for a Phase III clinical trial of the company's BetaSiteeyedrops. The study began in January and patient treatments couldbe completed by the end of this year.
(c) 1997 American Health Consultants. All rights reserved.